Kestra Medical Technologies, Ltd. Common Stock (KMTS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.71B
Last updated: Nov 17, 2026 at 11:05 AM ET
Kestra Medical Technologies, Ltd. Common Stock (KMTS) Stock Forecast
Analysts expect Kestra Medical Technologies, Ltd. Common Stock (KMTS) to earn -$2.45 per share in the fiscal year ending Apr 30, 2027, on revenue of $140.85M. Of 9 analysts, 8 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Apr 30, 2027 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 89% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 6 | 66.7% |
| Hold | 1 | 11.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 39.1%.
- Fiscal year ending Apr 30, 2027
- -$2.45
- EPS consensus, revenue $140.85M
- Fiscal year ending Apr 30, 2028
- -$2.06
- EPS consensus, revenue $195.99M
- Next report
- Dec 11, 2026
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Apr 30, 2027 | -$2.45 | -$2.46 to -$2.44 | 2 | $140.85M | $140.40M to $141.04M | 9 |
| Apr 30, 2028 | -$2.06 | -$2.06 to -$2.05 | 2 | $195.99M | $190.22M to $200.54M | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.58 for the quarter ending Jan 31, 2027 to -$0.54 for the quarter ending Apr 30, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Jan 31, 2027 | -$0.58 | -$0.58 to -$0.57 | 2 | $35.49M | $35.00M to $36.00M | 9 |
| Apr 30, 2027 | -$0.54 | -$0.60 to -$0.54 | 11 | $43.19M | $40.08M to $45.15M | 11 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 4 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Apr 30, 2027 | 0 | 2 |
| Fiscal year ending Apr 30, 2028 | 0 | 1 |
| Quarter ending Jan 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Apr 30, 2027 has worsened from -$2.31.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Apr 30, 2027 | -$2.45 | -$2.45 | -$2.45 | -$2.31 | -$2.31 | N/A |
| Fiscal year ending Apr 30, 2028 | -$2.06 | -$2.06 | -$2.06 | -$2.02 | -$2.02 | N/A |
| Quarter ending Jan 31, 2027 | -$0.58 | -$0.58 | -$0.58 | -$0.57 | -$0.57 | N/A |
Frequently Asked Questions About KMTS
What is the KMTS stock forecast?
Consensus analyst estimates put Kestra Medical Technologies, Ltd. Common Stock's EPS at -$2.45 for the fiscal year ending Apr 30, 2027, on revenue of $140.85M. The consensus rating from 9 analysts is Buy.
How do analysts rate KMTS stock?
Of 9 analysts covering Kestra Medical Technologies, Ltd. Common Stock, 2 rate it Strong Buy, 6 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KMTS next year?
For the fiscal year ending Apr 30, 2027, the consensus EPS estimate is -$2.45, with estimates from -$2.46 to -$2.44 from 2 analysts. For the fiscal year ending Apr 30, 2028, the consensus EPS estimate is -$2.06, with estimates from -$2.06 to -$2.05 from 2 analysts.
What revenue do analysts expect from Kestra Medical Technologies, Ltd. Common Stock next year?
For the fiscal year ending Apr 30, 2027, the consensus revenue estimate is $140.85M, with estimates from $140.40M to $141.04M. For the fiscal year ending Apr 30, 2028, the consensus revenue estimate is $195.99M, with estimates from $190.22M to $200.54M.
How many analysts cover KMTS?
9 analysts rate Kestra Medical Technologies, Ltd. Common Stock stock, and 2 analysts estimate its EPS for the fiscal year ending Apr 30, 2027.
KMTS pages: Overview, Forecast, Financials, Competitors